2015—2017年我院口服降压药物应用分析
|
摘要
目的:分析2015—2017年我院口服降压药物的应用情况,促进临床合理用药。方法 :对2015—2017年我院口服降压药物的种类、用量、销售金额、用药频度(DDDs),药品日均费用(DDC)及排序比(B/A)等进行统计、分析。结果 :我院口服降压药物销售金额和DDDs呈逐年增长趋势;销售金额排序前3位的药品为缬沙坦、左氨氯地平、氨氯地平;DDDs排序前3位为左氨氯地平、硝苯地平、氨氯地平。结论:近年来,我院口服降压药物的使用基本合理,但应加强监管。
Objective: To analyze the application of oral antihypertensive drugs in our hospital from 2015 to 2017, so as to promote clinical rational drug use. Methods: The types, dosages, sales amount, defined daily doses(DDDs), daily average cost(DDC) and sorting ratio(B/A) of oral antihypertensive drugs in our hospital from 2015 to 2017 were statistically analyzed. Results: The sales amount and DDDs of oral antihypertensive drugs in our hospital showed an increasing trend year by year. The top three drugs in the sales amount were valsartan, levamlodipine and amlodipine, and the top three drugs in the DDDs were levamlodipine, nifedipine and amlodipine. Conclusion: In recent years, the use of oral antihypertensive drugs in our hospital is basically reasonable, but supervision should be strengthened.
Objective: To analyze the application of oral antihypertensive drugs in our hospital from 2015 to 2017, so as to promote clinical rational drug use. Methods: The types, dosages, sales amount, defined daily doses(DDDs), daily average cost(DDC) and sorting ratio(B/A) of oral antihypertensive drugs in our hospital from 2015 to 2017 were statistically analyzed. Results: The sales amount and DDDs of oral antihypertensive drugs in our hospital showed an increasing trend year by year. The top three drugs in the sales amount were valsartan, levamlodipine and amlodipine, and the top three drugs in the DDDs were levamlodipine, nifedipine and amlodipine. Conclusion: In recent years, the use of oral antihypertensive drugs in our hospital is basically reasonable, but supervision should be strengthened.
引文
[1]张福康,陆再华,杨妍华,等.高血压患者用药的调查与分析[J].中国执业药师,2015,12(3):6-8,11.
[2]席宇飞,吴英理,归成,等.2010-2014年上海地区医院抗高血压药物利用趋势[J].川北医学院学报,2017,32(1):120-124.
[3]吴晨虹,刘小龙,蔡晓霞,等.三甲医院门诊药房2016年抗高血压药使用情况分析[J].临床合理用药杂志,2017,10(31):113-115.
[4]倪炎,周端,魏易洪,等.中西医互补认识和治疗高血压病[J].世界中西医结合杂志,2015,10(7):1003-1005.
[5]刘诗,樊光辉.中西医结合治疗老年高血压的临床研究进展[J].中西医结合心脑血管病杂志,2013,11(7):861-862.
[6]陈明.大剂量缬沙坦治疗急性心肌梗死后心室重构的临床效果[J].中国循证心血管医学杂志,2014,6(3):339-340,343.
[7]崔贞玉,韩素霞.ARB与ACEI改善心肌梗死患者心室重构的Meta分析[J].实用药物与临床,2014,17(2):139-146.
[8]罗加庆.血管紧张素Ⅱ受体拮抗剂的心血管保护作用[J].现代诊断与治疗,2013,24(11):2619-2620.
[9]郭明,周晓斌,田军.血管紧张素Ⅱ受体拮抗剂与他汀对慢性充血性心衰患者左心室重构的影响[J].武警后勤学院学报(医学版),2013,22(7):586-590.
[10]马金辉,王志飞,谢雁鸣,等.真实世界大数据30034例高血压病住院患者中西医诊疗规律初探[J].中国中药杂志,2014,39(18):3435-3440.
[11]冯秋婷,钱晓军,徐欣,等.氨氯地平通过影响心房钠尿肽抑制心肌细胞的重构[J].实用医学杂志,2014,30(15):2360-2363.
[12]郭木恭,余庆耀,林巧銮.左旋氨氯地平对高血压患者左心室肥厚影响的研究[J].实用医药杂志,2015,32(9):823-824.
[2]席宇飞,吴英理,归成,等.2010-2014年上海地区医院抗高血压药物利用趋势[J].川北医学院学报,2017,32(1):120-124.
[3]吴晨虹,刘小龙,蔡晓霞,等.三甲医院门诊药房2016年抗高血压药使用情况分析[J].临床合理用药杂志,2017,10(31):113-115.
[4]倪炎,周端,魏易洪,等.中西医互补认识和治疗高血压病[J].世界中西医结合杂志,2015,10(7):1003-1005.
[5]刘诗,樊光辉.中西医结合治疗老年高血压的临床研究进展[J].中西医结合心脑血管病杂志,2013,11(7):861-862.
[6]陈明.大剂量缬沙坦治疗急性心肌梗死后心室重构的临床效果[J].中国循证心血管医学杂志,2014,6(3):339-340,343.
[7]崔贞玉,韩素霞.ARB与ACEI改善心肌梗死患者心室重构的Meta分析[J].实用药物与临床,2014,17(2):139-146.
[8]罗加庆.血管紧张素Ⅱ受体拮抗剂的心血管保护作用[J].现代诊断与治疗,2013,24(11):2619-2620.
[9]郭明,周晓斌,田军.血管紧张素Ⅱ受体拮抗剂与他汀对慢性充血性心衰患者左心室重构的影响[J].武警后勤学院学报(医学版),2013,22(7):586-590.
[10]马金辉,王志飞,谢雁鸣,等.真实世界大数据30034例高血压病住院患者中西医诊疗规律初探[J].中国中药杂志,2014,39(18):3435-3440.
[11]冯秋婷,钱晓军,徐欣,等.氨氯地平通过影响心房钠尿肽抑制心肌细胞的重构[J].实用医学杂志,2014,30(15):2360-2363.
[12]郭木恭,余庆耀,林巧銮.左旋氨氯地平对高血压患者左心室肥厚影响的研究[J].实用医药杂志,2015,32(9):823-824.